Literature DB >> 17636123

Structural basis of antigenic escape of a malaria vaccine candidate.

Sheetij Dutta1, Seung Yeon Lee, Adrian H Batchelor, David E Lanar.   

Abstract

Antibodies against the malaria vaccine candidate apical membrane antigen-1 (AMA-1) can inhibit invasion of merozoites into RBC, but antigenic diversity can compromise vaccine efficacy. We hypothesize that polymorphic sites located within inhibitory epitopes function as antigenic escape residues (AER). By using an in vitro model of antigenic escape, the inhibitory contribution of 24 polymorphic sites of the 3D7 AMA-1 vaccine was determined. An AER cluster of 13 polymorphisms, located within domain 1, had the highest inhibitory contribution. Within this AER cluster, antibodies primarily targeted five polymorphic residues situated on an alpha-helical loop. A second important AER cluster was localized to domain 2. Domain 3 polymorphisms enhanced the inhibitory contribution of the domain 2 AER cluster. Importantly, the AER clusters could be split, such that chimeras containing domain 1 of FVO and domain 2 + 3 of 3D7 generated antisera that showed similarly high level inhibition of the two vaccine strains. Antibodies to this chimeric protein also inhibited unrelated strains of the parasite. Interstrain AER chimeras can be a way to incorporate inhibitory epitopes of two AMA-1 strains into a single protein. The AER clusters map in close proximity to conserved structural elements: the hydrophobic trough and the C-terminal proteolytic processing site. This finding led us to hypothesize that a conserved structural basis of antigenic escape from anti-AMA-1 exists. Genotyping high-impact AER may be useful for classifying AMA-1 strains into inhibition groups and to detect allelic effects of an AMA-1 vaccine in the field.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636123      PMCID: PMC1941496          DOI: 10.1073/pnas.0701464104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody.

Authors:  A M Coley; K Parisi; R Masciantonio; J Hoeck; J L Casey; V J Murphy; K S Harris; A H Batchelor; R F Anders; M Foley
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

Authors:  Mark E Polhemus; Alan J Magill; James F Cummings; Kent E Kester; Chris F Ockenhouse; David E Lanar; Sheetij Dutta; Arnoldo Barbosa; Lorraine Soisson; Carter L Diggs; Sally A Robinson; John D Haynes; V Ann Stewart; Lisa A Ware; Clara Brando; Urszula Krzych; Robert A Bowden; Joe D Cohen; Marie-Claude Dubois; Opokua Ofori-Anyinam; Els De-Kock; W Ripley Ballou; D Gray Heppner
Journal:  Vaccine       Date:  2007-03-26       Impact factor: 3.641

3.  Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes.

Authors:  P E Crewther; M L Matthew; R H Flegg; R F Anders
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

4.  Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli.

Authors:  Sheetij Dutta; P V Lalitha; Lisa A Ware; Arnoldo Barbosa; J Kathleen Moch; Meredith A Vassell; Bader B Fileta; Svetlana Kitov; Nelly Kolodny; D Gray Heppner; J David Haynes; David E Lanar
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

5.  Erythrocytic malaria growth or invasion inhibition assays with emphasis on suspension culture GIA.

Authors:  J David Haynes; J Kathleen Moch; Douglas S Smoot
Journal:  Methods Mol Med       Date:  2002

6.  Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen.

Authors:  Spencer D Polley; Watcharee Chokejindachai; David J Conway
Journal:  Genetics       Date:  2003-10       Impact factor: 4.562

7.  Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites.

Authors:  Sheetij Dutta; J David Haynes; J Kathleen Moch; Arnoldo Barbosa; David E Lanar
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-02       Impact factor: 11.205

8.  Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria.

Authors:  Spencer D Polley; Tabitha Mwangi; Clemens H M Kocken; Alan W Thomas; Sheetij Dutta; David E Lanar; Ed Remarque; Amanda Ross; Thomas N Williams; Gabrielle Mwambingu; Brett Lowe; David J Conway; Kevin Marsh
Journal:  Vaccine       Date:  2004-12-16       Impact factor: 3.641

9.  Crystal structure of the malaria vaccine candidate apical membrane antigen 1.

Authors:  Juan Carlos Pizarro; Brigitte Vulliez-Le Normand; Marie-Laure Chesne-Seck; Christine R Collins; Chrislaine Withers-Martinez; Fiona Hackett; Michael J Blackman; Bart W Faber; Edmond J Remarque; Clemens H M Kocken; Alan W Thomas; Graham A Bentley
Journal:  Science       Date:  2005-02-24       Impact factor: 47.728

10.  Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1.

Authors:  Christine R Collins; Chrislaine Withers-Martinez; Graham A Bentley; Adrian H Batchelor; Alan W Thomas; Michael J Blackman
Journal:  J Biol Chem       Date:  2006-12-27       Impact factor: 5.157

View more
  69 in total

Review 1.  Vaccines for malaria: how close are we?

Authors:  Mahamadou A Thera; Christopher V Plowe
Journal:  Annu Rev Med       Date:  2011-11-10       Impact factor: 13.739

2.  Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.

Authors:  Karen S Harris; Christopher G Adda; Madhavi Khore; Damien R Drew; Antonina Valentini-Gatt; Freya J I Fowkes; James G Beeson; Sheetij Dutta; Robin F Anders; Michael Foley
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

3.  Vaccine design via nonnegative lasso-based variable selection.

Authors:  Zonghui Hu; Dean A Follmann; Kazutoyo Miura
Journal:  Stat Med       Date:  2015-02-02       Impact factor: 2.373

4.  Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies.

Authors:  K Sony Reddy; Alok K Pandey; Hina Singh; Tajali Sahar; Amlabu Emmanuel; Chetan E Chitnis; Virander S Chauhan; Deepak Gaur
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

5.  Development of quantitative suspension array assays for six immunoglobulin isotypes and subclasses to multiple Plasmodium falciparum antigens.

Authors:  Marta Vidal; Ruth Aguilar; Joseph J Campo; Carlota Dobaño
Journal:  J Immunol Methods       Date:  2018-01-31       Impact factor: 2.303

6.  Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.

Authors:  Kazutoyo Miura; Raul Herrera; Ababacar Diouf; Hong Zhou; Jianbing Mu; Zonghui Hu; Nicholas J MacDonald; Karine Reiter; Vu Nguyen; Richard L Shimp; Kavita Singh; David L Narum; Carole A Long; Louis H Miller
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

7.  Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

Authors:  Mark A Pierce; Ruth D Ellis; Laura B Martin; Elissa Malkin; Eveline Tierney; Kazutoyo Miura; Michael P Fay; Joanne Marjason; Suzanne L Elliott; Gregory E D Mullen; Kelly Rausch; Daming Zhu; Carole A Long; Louis H Miller
Journal:  Vaccine       Date:  2010-01-04       Impact factor: 3.641

8.  High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model.

Authors:  Sheetij Dutta; JoAnn S Sullivan; Katharine K Grady; J David Haynes; Jack Komisar; Adrian H Batchelor; Lorraine Soisson; Carter L Diggs; D Gray Heppner; David E Lanar; William E Collins; John W Barnwell
Journal:  PLoS One       Date:  2009-12-03       Impact factor: 3.240

9.  Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Matthew B Laurens; Abdoulaye K Kone; Ando B Guindo; Karim Traore; Mady Sissoko; Dapa A Diallo; Issa Diarra; Bourema Kouriba; Modibo Daou; Amagana Dolo; Mounirou Baby; Mahamadou S Sissoko; Issaka Sagara; Amadou Niangaly; Idrissa Traore; Ally Olotu; Olivier Godeaux; Amanda Leach; Marie-Claude Dubois; W Ripley Ballou; Joe Cohen; Darby Thompson; Tina Dube; Lorraine Soisson; Carter L Diggs; Shannon L Takala; Kirsten E Lyke; Brent House; David E Lanar; Sheetij Dutta; D Gray Heppner; Christopher V Plowe
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

10.  Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.

Authors:  Kwadwo A Kusi; Bart W Faber; Alan W Thomas; Edmond J Remarque
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.